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Abstract 
Drug delivery approaches have diversified over the last two decades with the 
emergence of nanotechnologies, smart polymeric systems and multi-modal 
functionalities. The intended target for specific treatment of disease is the key 
defining developing parameter. One such area which has undergone significant 
advancements relates to ocular delivery. This has been expedited by the 
development of material advancement, mechanistic concepts and through the 
deployment of advanced process technologies. This review will focus on the 
developments within lens-based drug delivery whilst touching on conventional and 
current methods of ocular drug delivery. A summary table will also provide quick 
reference to note the key findings in this area. In addition, the review also elucidates 
current theranostic and diagnostic approaches based on ocular lenses.  
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Introduction: 
Despite being an easy accessible organ, the physiology and anatomy of the eye 
poses demanding challenges with regards to ocular drug delivery (ODD). Anatomical 
and physiological (and to a certain degree biochemical) barriers provide extensive 
protection from foreign matter[1,2]. Due to this, effective delivery devices must be 
designed and developed in order to target specific ophthalmic tissues and to help 
control ocular disease progression. The arena of ODD is constantly evolving with 
potential to exploit the emerging recognition of nano-engineering and polymer 
science. Over recent years, there has been emphasis on novel, non-evasive delivery 
devices for not only controlled and sustained ODD but also with applications 
extended to systemic delivery and theranostics[3-7], all showing promising results with 
the potential development of new ocular products in the near future. 
This review will touch upon conventional approaches for ocular drug delivery and 
focus in on the use of contact lenses as drug delivery devices for topical drug 
delivery. The review also provides tabulated details for easy reference on the 
developments in this area. In addition, future perspectives for drug delivery are 
provided.  
Eye Structure:   
The eye is a spherical organ consisting of two “spheres”; anterior and posterior 
chambers. It is made up of several structures; all with specific functions with regards 
to the physiology of the eye.  
The anterior segment makes up the front of the eye whilst the posterior segment 
makes up 2/3 of the organ. The outermost structure, the cornea, is one of the most 
important structures of the eye with respect to ODD. It works predominantly to 
protect the front of the eye and focus light into the eye[8]. Moreover, it is the barrier 
that pharmaceutical formulations/actives would pass through in order to enter the 
eye and have therapeutic effect. It is made up of 5 layers, each varying in thickness 
(500µm thick in total)[8]. Another vital part of the eye for ODD is the ciliary body which 
is located between the lens and choroid (part of the posterior segment). It produces 
the aqueous humour (AH); a transparent gel which occupies the space between the 
lens and the cornea (aka the posterior chamber), which believed to has 
immunological function to defend against pathogens. Also, it provides nutrients (i.e. 
amino acids and glucose) to the cornea and the lens[9].  The AH passes through the 
posterior chamber and move through the pupil into the anterior chamber. The 
production and drainage of the AH via the Trabecular meshwork maintains the 
correct intraocular pressure (IOP); 12-22 mmHg[10]. If this pressure is compromised, 
then the consequence can be severe, as with glaucoma. The trabecular meshwork is 
located where the cornea meets the iris and allows the AH to drain into a set of tubes 
called the Canal of Schlemm to systemic blood flow.  
Other structures that make up the anterior segment of the eye include the iris, sclera, 
lens, pupil and conjunctiva.  The posterior segment houses the retina, macula, fovea 
and optic nerve.  
Routes of Administration in Ocular Drug Delivery 
There are 3 main routes for drug delivery to the targeting region of the eye; topical, 
systemic and intraocular. The topical route (corneal absorption) is the primary chose 
due to high patient compliance and ease of administration. Regardless of being a 
non-invasive method; physiological hurdles such as high teat turnover rate (16% per 
minute) and tear dilution reduces the bioavailability of the drug with less than 5% of 
the drug penetrating the cornea. Nasolacrimal drainage due to excess product on the 
corneal tear film can also occur. The precorneal film destabilises upon administration 
causing blinking, resulting in the drug being pumped into the systemic circulation.  
Systemic administration of ocular drugs (e.g. via tablets) is often discarded due to 
the very small ratio of the eye to the entire body. Many ocular drugs also have dual 
functions e.g. timolol is an antiglaucoma drug but also acts as a non-selective beta-
adrenergic blocking agent with action on the sympathetic nervous system which can 
cause a decrease in blood pressure and slows cardiac activity and lung function[11]. 
 
The anatomical barriers of the various structures that make up the eye and the 
physiology of these structures make it challenging to achieve precise drug delivery. 
Intraocular approaches are utilised to delivery drugs directly to the posterior segment 
of the eye. Due to structural barriers of the cornea and conjunctiva, injections via the 
intravitreal route or periocular route can be practical and more effective. Despite low 
patient compliance, these injections are capable of delivering therapeutic agents 
directly to the target tissue; bypassing the anatomical barriers of the eye. Using a 
very fine needle (30-G), the drug solution is injected directly to the vitreous and 
retina. Regardless of delivery of drug at high concentrations directly to the targeted 
region, drug distribution is not homogenous. Another challenge this is met with 
intravitreal injections concerns the clearance of the drug. Direct delivery to the 
vitreous means the drug clearance occurs either via the anterior pathway or posterior 
pathway. The aqueous clearance pathway consists of the drug diffusing through the 
AH and is subsequently drained whilst the posterior pathway involves drug 
management across the blood retinal barrier; requiring active transport[12]. Due to 
this, hydrophilic solutes with high molecular weight remain in the vitreous humour for 
extended period of time. This, alongside repetitive perforation of the eye tissue can 
lead to the development of conditions such as endophthalmitis and cataracts.   
 
Conventional Ocular Delivery Methods 
The following section will look into conventional and current approaches to topical 
ocular drug delivery (Figure 1).  
 
Eye Drops 
Eye drops make up approximately 90% of all topical ocular formulations; in the form 
of solutions, suspensions and emulsions[13]. Due to the nature of the targeting tissue 
and the mode of application, extreme care is needed for such formulations to be 
isotonic (same osmotic concentration/pressure as the targeted tissue), non-invasive 
and sterile. Ease of formulation and patient compliance make eye drops favourable 
to both manufactures and patients alike. Despite this, there are some drawbacks as 
less than 5% of the drug from a typical eye drop (50µL) actually permeates the 
cornea[14]. This is due to anatomical, physiological, metabolic and biochemical 
properties and barriers of the eye; resulting in drug loss via nasolacrimal drainage[14]. 
Consequently, frequent administration of drug is needed in order to achieve the 
therapeutic drug levels in the eye[15].  
In a bid to improve the residence time of the drug in the eye, additives such as 
viscosity enhancers (e.g. Hydroxypropyl methylcellulose, polyethylene glycol), 
permeability enhancers (e.g. benzalkonium chloride, ethylenediaminetetraacetic acid 
(EDTA)) and cyclodextrins (e.g. Brij® 78) have been incorporated into formulations. 
Cyclodextrins increase the water solubility of lipophilic drugs (and aqueous stability) 
therefore increase drug bioavailability and absorption. Aceclofenac (a topical non-
steroidal anti-inflammatory drug (NSAIDs)) used to treat anterior chamber 
inflammation along with pain and inflammation associated with post-operative 
treatment. Preservatives such as methyl paraben (MP), propyl paraben (PP), 
benzalkonium chloride (BAC) and viscosity enhancer (Hydroxypropyl methylcellulose 
(HPMC)) were added to decrease the permeability coefficient of aceclofenac. 
Moreover, the apparent permeability coefficient was also reduced by increasing the 
solution pH value from 6.0 to 8.0[16]. The combination of MP, PP and BAC enabled 
an increase in the transcorneal permeation of this active drug whilst 
pharmacodynamics in vivo studies showed this novel formulation was effective that it 
is commercially available (Voltaren® ophthalmic drops 0.1% (diclofenac sodium)).   
Some actives (e.g. dexamethasone[17]) and metabolites (e.g. prednisolone[18]) are 
poorly-soluble or insoluble in aqueous media. To improve their solubility, these 
materials can be complexed with cyclodextrins (CDs) to form water soluble inclusion 
complexes. CDs are amphiphilic (has hydrophobic and hydrophilic regions) cyclic 
oligosaccharides extensively used to improve the solubility and stability of some 
ocular drugs such as dexamethasone[17], dorzolamide[19,20], ciprofloxacin[21] and 
cyclosporine A[22]. Nijhawan and Agarwal, have developed an ophthalmic preparation 
containing ciprofloxacin by inclusion complexes of ciprofloxacin hydrochloride with 
hydroxypropyl-β-CDs using freeze drying method. The complexes exhibited 
increased water solubility of the drug, stability, biological activity and ocular tolerance 
when compared to a commercially available ocular formulation[21]. Dimethyl-β-CDs is 
another type of CDs was used for ocular delivery of prednisolone with the addition of 
HPMC. Prednisolone (water insoluble corticosteroid) manipulates the body’s immune 
system response conditions such as arthritis, cancers and eye conditions (e.g. 
keratitis). Couto et al exploited the amphiphilic nature of dimethyl-β-CDs to form 
complex with prednisolone and HPMC. Dimethyl-β-CDs increased drug water 
solubility and maintained pseudoplastic behaviour in the suspension that presented a 
d90 lower than 90 µm (particle size)[18]. 
Emulsions 
Addition of additives is one approach to improve liquid formulations for topical drug 
delivery to the eye. Modifying the physical properties (e.g. membrane permeability, 
cellular uptake) of the ocular cells, in an attempt to increase drug penetration and 
drug presence at site of action is another approach. Emulsions are often used to 
improve the solubility of poorly soluble drugs. They are heterogeneous dispersions of 
oil in water (o/w) or water in oil (w/o), usually with the addition of surfactants or co-
surfactants[23]. Emulsions are considered to be advantageous to topical ODD due to 
their ability to increase membrane permeability and cellular uptake due to the 
surfactants[24]. The underlying theory for this revolves around the fact that surfactants 
interact with the lipid bilayer around ocular cells modifying their physiochemical 
properties. Surfactant saturation in the lipid bilayer consequently leads to the 
formation of micelles which act to remove lipids from the cell membrane by 
solubilisation that in turn increase the membrane permeability. This fundamental 
principle has led to numerous studies that have yielded promising results; increased 
drug concentration in vital structures of the eye[25,26].  There are various ways of 
categorising emulsions; the most common is via droplet size. Nano-(submicron) 
emulsions usually contain droplets 100-1000nm in diameter whilst droplets in micro-
emulsions range from 10nm to 100nm. Whilst both demonstrate more stability than 
simple emulsions and are low in viscosity; there are some crucial differences 
between the types of emulsions which ultimately affect the final purpose of the 
emulsion. Micro-emulsions spontaneously form via self-assembly whilst nano-
emulsions are formed intentionally via mechanical shearing. The stability of these 
emulsions is a critical attribute; nano-emulsions are kinetically stable unlike micro-
emulsions which are thermodynamically stable. 
 
The use of emulsions in topical ODD was first investigated in 1989, for the treatment 
of glaucoma. Incorporation of surfactant lecithin to an o/w micro-emulsion increased 
the bioavailability of timolol in the aqueous humour, when administered to the 
conjunctival sac of rabbits. When compared to a formulation without lecithin, there 
was 3.5 times much drug present in the aqueous humour[24]. Lidocaine, (a 
hydrophobic drug), has been entrapped in various oil-in-water micro-emulsions (~10-
20nm particle size) before dispersion through pHEMA lenses[27]. Gulsen et al found 
that these particles gave a burst release at first (35% of drug) followed by 80% and 
95% of the drug being released within 4 days and 9 days, respectively. 
More recently, topical ODD with respect to emulsions have turned to nano-emulsions 
(NE); o/w or w/o. The dispersed phase is in the form of nanodroplets 50-200nm in 
diameter heterogeneously dispersed within the external immiscible phase. These 
formulations are useful for the delivery of both hydrophilic and lipophilic drugs[28], 
however they are still subject to emulsion instabilities; coalescence, flocculation and 
Otswald ripening. Nano-emulsions have been investigated for the delivery of wide 
range of bioactive molecules like antibacterial agents (e.g. cetalkonium chloride[29]) 
and anti-glaucoma drugs (e.g. dorzolamide hydrochloride[30]). The anti-glaucoma 
drug (delta-8-tetrahydrocannabinol) was one of first drugs to be successfully 
encapsulated into NE for topical ODD. Delta-8-tetrahydrocannibinol (antiglaucoma 
lipophilic drug) was incorporated into the oil phase of a submicron emulsion (mean 
droplet size: 130±41nm) and showed an intense and long lasting reduction effect for 
the intraocular pressure. This formulation remains stable after steam autoclaving and 
after storage for 9 months[31]. These promising results sparked a search for more 
biocompatible actives for extended action in the eye.   
Incorporation of surfactants ultimately affect the charge of formulation; due to this, 
cationic surfactants have been found to increase bioavailability of drugs due to 
electrostatic interactions between cornea and membrane protein (mucin), hence 
increasing drug residence time in the cornea[32,33]. However, their toxicity is a 
disadvantage that needs to be overcome; very few have been approved for ocular 
use.   
Novagali, a French pharmaceutical company, has developed a cationic NE that 
improves drug delivery by exploiting the negative charge of ophthalmic cells at 
physiological pH. The use of positively charged formulations can increase the 
electrostatic interactions, consequently increase the residence time. This innovative 
technology has already been used to deliver cyclosporin A (Cyclokat® and 
Vekacia®)[34] with several more applications in the pipeline including latanoprost 
delivery for glaucoma treatment[35].  
More recently, emulsion cross-linking and formulation optimisation via factorial 
design was utilised to improve precorneal residence time and drug penetration of the 
hydrophilic antibiotic doxycycline hydrochloride (DOX HC). The nanoparticles (331-
850 nm size range) encapsulated around 45-80% of DOX HC. This formulation 
showed sustained release kinetic of DOX HC with significant antibacterial effect on 
strains of Staphylococcus aureus and Escherichia coli (p<0.011) as compared to 
DOX HC aqueous solution[3].  
Viscoelastic gels 
Viscoelastic gels are hydrophilic polymeric matrices capable of swelling after water 
uptake, allowing drug diffusion in and out of the system. Once swollen, the polymeric 
matrix is approximately 60-90% water[36]. These gels can form before administration 
or in situ; however, more emphasis has been placed on the latter due to ease of 
administration and precision of gels compared to solutions [37]. Phase transition on 
the ocular surface increases formulation residence time, and hence increases drug 
exposure. Both natural polymers (e.g. gelatin[38], dextran[39], alginate[40], 
chitosan[38,41], polysaccharides[42]) and synthetic polymers (e.g. poly -hydroxyethyl 
methacrylate[43,44], glycolic acid[45,46]  have been used as swellable matrices. It is 
important to note that selection of polymer is crucial due to the effect on the final gel 
properties. Due to different polymers having different advantageous properties, it is 
common to blend two or more polymers to obtain optimised gel systems. For 
example, chitosan has been blended with gelatin and glycerol phosphate to develop 
a thermoresponsive gel which enhanced in vitro and in vivo compatibility for the 
delivery of latanoprost[41]. In vivo release studies in rabbit models demonstrated 
steady drug concentration in the aqueous humour without burst release. This 
sustained release system continued for 8 days; with IOP being restored within this 
time period and maintained for further 31 days[41].  
Chitosan has also been combined with poly (N-isopropylacrylamide) (PNIPAM) to 
exploit the thermosensitive nature of PNIPAM to develop an in situ thermoresponsive 
HG for the delivery of antiglaucoma drug timolol maleate (TM)[47]. In vivo studies 
showed increased drug permeation in rabbit cornea in the absence of any 
cytotoxicity. Compared to conventional TM eye drops, although the onset of action 
was observed at t=0.5 h, the HG demonstrated stronger IOP reduction, highlighting 
the potential of chitosan-PNIPAM blend of improving efficacy of TM[47].   
Temperature is not the only stimulus that has been employed to trigger the swelling 
of gel matrices; pH triggered systems (e.g. Poly acrylic acid (PAA)[48,49]), ionic 
strength (e.g. sodium alginate[4,50,51]) and enzyme substrate systems have also been 
evaluated.  PAA is a polymer which has a large array of applications, including 
thickening agent, suspending agent and emulsifying agent. At physiological 
conditions and aqueous environment, PAA is an anionic polymer and is commonly 
combined with hydroxypropyl methylcellulose (HPMC) to increase the viscosity of the 
formulation, ultimately increasing drug residence time[48].  
Dubey et al studied the in vivo IOP lowering activity of PAA (carbopol C 934p)-
HPMC stimuli sensitive gelling system[48]. Once administered to the eye, the pH 
changed accordingly causing the gel to increase in viscosity, providing sustained 
release of drug. In vitro release studies demonstrated zero order release; 90% of 
drug (TM, brimonidine tartrate (BT)) was released within 8 hours; exhibiting 
sustained release. The ability of the novel stimuli-sensitive TM and BT loaded HG to 
lower IOP was compared to a marketed formulation. The marketed formulation 
lowered IOP but failed to maintain this. The gelling system with a combination of 
both drugs achieved greater IOP reduction which was maintained for a longer time 
than the marketed formulation[48].  
Sodium alginate (SA) is a viscosity enhancer often used in drug delivery due to its 
ability to undergo gelation as a result of changes in ionic strength[52]. SA is 
susceptible to phase change when exposed to divalent ions such as magnesium and 
calcium; an ion which is abundant in tear fluid[52,53]. This property of SA has been 
exploited to increase drug residence time. For instance, SA along with methyl 
cellulose was successfully used to formulate a novel in situ gelling matrix for 
therapeutically efficacious sustained release and stable ophthalmic drug delivery of 
moxifloxacin hydrochloride[50].  There are already some marketed formulations for 
topical ocular delivery of timolol maleate. Timoptic-XE® is based on anionic 
heteropolysaccharide derived from gellan gum. In this product, an aqueous solution 
of gellan gum, in the presence of a cation (in precorneal tear fluid), has the ability to 
gel enabling prolonged exposure to the product, increasing drug release.  
 
Innovative Systems 
Implants 
Ocular implants are effective drug delivery devices which are able to sustain drug 
delivery over months and even years. These devices are loaded with therapeutic 
agents and are surgically inserted to the eye at the target site. The main advantage 
of these systems is they serve dual purpose; the implants can act as controlled 
delivery systems but also help maintain therapeutic concentrations in the eye. Thee 
material from which these implants are made can differ between non-biodegradable 
(e.g. polyvinyl alcohol (PVA), silicon) and biodegradable (PLGA, Polylactic acid) 
(PLA)). PVA and ethylene vinyl acetate have been utilised in a commercial ocular 
implant to achieve the sustained delivery of antiviral drug ganciclovir. The Vitrasert® 
Implant (containing a ganciclovir tablet) is surgically inserted and can be removed 
and replaced following exhaustion of drug; often after 5 to 8 months. The PVA 
provides a semi-permeable matrix allowing drug diffusion whilst ethylene vinyl 
acetate is an impervious layer; providing the sustained release of ganciclovir.  
 
Renexus® is a non-vitreous implant used in the treatment of retinitis pigmentosa and 
age-related macular degeneration. The non-biodegradable implant is transfected 
with a plasmid encoding ciliary neurotrophic factors loaded into human cells. These 
encapsulated cells releases the factors in the posterior segment of the eye for the 
treatment of posterior conditions.   
 
Biodegradable implants are preferred due to their ability to degrade in the body (into 
water and carbon dioxide) after depletion of drug. Polymers PLA, PLG and PLGA are 
frequently researched and used as a result of their biocompatibility and long shelf life 
with respect degradation. Ozurdex® has been approved by the FDA for the 
treatment of diabetic macular edema. This biodegradable rod-shaped implant 
contains dexamethasone which delivers drug delivery to the posterior segment[54].  
 
Natu et al have developed dorzolamide-loaded device which can be surgically 
introduced into the eye. In vivo testing demonstrated more efficient lowering of IOP 
in rabbit eyes compared to topical delivery of dorzolamide.  
 
Iontophoresis 
Ocular iontophoresis utilises a low electrical current to drive ionised drugs into ocular 
cells or tissue. Anodes are used to drive positively charged drugs through tissue and 
cathodes for negatively charged molecules. Iontophoresis is a painless, fast, non-
invasive drug delivery method and is capable of delivering therapeutic 
concentrations of drug to the targeted tissue; increasing drug bioavailability and 
decreasing the frequency of dosing. The first study to apply this theory was reported 
in 1943 for transcleral delivery[55]. Due to constant evolution in the pharmaceutical 
industry and ocular field has developed a novel system in which iontophoresis is 
used to delivery therapeutic concentrations of drug to both anterior and posterior 
segment. The Eyegate II delivery System by EyeGate Pharmaceutical Inc employs 
an inert electrode to ionise water to produce hydroxide or hydronium ions required to 
drive charge drug molecules. This system has been used to delivery dexamethasone 
phosphate solution for the treatment of dry eye and is currently in phase 3 clinical 
trials[56].  
 
Microneedles 
 
Microneedles (MNs) are drug delivery devices which have rapidly developed in the 
last decade. These devices consist of very small needles capable of piercing tissue, 
creating micropaths through which drug molecules can permeate through[57-59]. The 
rapid development of these devices has shown the potential in enhanced intraocular 
drug delivery. Solid MNs (500-700µm) were coated with pilocarpine and showed 
rapid dissolution of drug within scleral tissue within 30 seconds of insertion. In vitro 
analysis proved the mechanical strength of the MNs whilst showing lack of 
complications that are usually associated with intraocular injections and systemic 
administration[60]. More recently, stainless steel MNs were used to study the delivery 
of bevacizumab for treatment of corneal neovascularisation[61]. MNs 400µm in height 
were coated in drug and inserted into New Zealand white rabbits. Rabbit eyes 
treated with eye drops showed a 6% reduction of neovascularisation after 18 days 
whilst eyes treated with MNs showed a 44% reduction compared to untreated eyes.  
 
Thakur et al have developed rapidly dissolving MNs for delivery via intrastromal or 
intrascleral route[62]. High molecular weight PVP arrays 800µm in height showed to 
withstand higher forces than low molecular weight arrays. MNs using high molecular 
weight PVP showed complete dissolution in 180 seconds compared to the 10 
seconds of low molecular weight PVP. The use of MN in corneal and scleral tissues 
showed the enhancement of macromolecules delivery following puncturing by MNs; 
with drug molecules forming depots in the tissue; enhancing sustained drug delivery.  
 
 
Contact lenses 
Despite the efforts to improve conventional methods to achieve extended drug 
exposure time to ophthalmic tissue, these methods are no longer adequate for 
treating ocular conditions. Regardless of patient compliance, ease of administration 
and formulation, there are some fundamental drawbacks with respect to the 
formulation itself (e.g. eye-drops, in situ gels). The extended residence time, blurred 
vision and poor availability (due to nasolacrimal drainage) can limit the 
application/administration of such formulations to specific times (e.g. night)[63]. Many 
systems (e.g. microneedles) also have low patient compliance, which can alter drug 
administration and reduce drug bioavailability. Appreciating these limitations has 
shifted focus onto developing various ocular devices. The most common device to 
emerge from this research is contact lens (CL). Soft contact lenses are 
polymeric/hydrogel discs which are inserted into the eye and come into contact with 
the cornea; held to the corneal tear film by surface tension[64]. The main use of CLs 
is for vision correction (e.g. conditions such as astigmatism and myopia)[65] but uses 
have also been exploited in cosmetics/aesthetics as well as therapeutics and 
theranostics[66-69].  
The idea of CLs was first conceptualised by Sir John Herschel in 1832; with the first 
glass CL being developed in 1887. Principle breakthrough for soft contact lenses 
came in the 1960’s where Wichterle and Lim experimented with soft, water-
absorbent materials for biological use[70]. Advances in material development led to a 
breakthrough in the topical ocular drug delivery arena. The crosslinking of 2-
hydroxyehtyl methacrylate with ethylene glycol dimethylacrylate yielded a polymer 
(poly (hydroxyethyl methacrylate) (pHEMA)) capable of forming flexible hydrophilic 
HG’s[65]. The ability of pHEMA to retain up to 38% water to form flexible matrices 
overcame the vital disadvantages met with earlier proposed rigid materials for 
contact lenses such as period of usage. Due to CO2 retention when eyes are closed, 
there is a prerequisite for CLs to have increased gaseous permeability.   
In 1999, material development led to monomers (e.g. tris(trimethylsiloxy) silane) 
being used to fabricate silicone hydrogels[71]. These lenses possessed increased 
oxygen permeability, unlike conventional pHEMA lenses and therefore could be worn 
for prolonged periods of time. Silicone lenses have more rigid structure, accordingly 
development and manufacture was much easier. Only in the last two decades, CLs 
have been considered as useful devices suitable for drug delivery for such drugs like 
antibiotics, NSAIDs and anti-glaucoma drugs. As a result, many concepts 
(conventional and novel) to alter HG lenses have been introduced to achieve 
sustained/extended ocular drug delivery. Timolol has been incorporated into contact 
lenses which exhibited a 12 hr of sustained release[72] while lidocaine-loaded contact 
lenses demonstrated a sustained released over 8 days[73]. Table 1 summarises 
some of the research carried out based on the use of contact lenses as drug delivery 
devices. 
 
Mechanisms of drug loading 
Soak and release 
One of the first attempts to develop drug loaded CLs involved soaking pre-prepared 
lenses in an aqueous drug solution, allowing drug to be taken into the hydrophilic 
matrix of the lens. This conventional method was first proposed over 40 years ago[74] 
and is now commonly used for delivery of anti-glaucoma drugs[75-78], 
antihistamines[79,80] and antibiotics[66]. Upon insertion in the eye, initial burst release 
of active is achieved followed by sustained release via diffusion. The drug solution 
can alternatively be topically applied to the eye with the lens in situ.  
Hillman et al were one of the first to utilise this method, using cholinergic anti-
glaucoma drug pilocarpine hydrochloride. A blend of vinyl pyrollidone/acrylic 
monomers were used as CL material. The resulting hydrophilic lens were soaked in 
a 1% drug solution and inserted into the eyes of patients with acute closed angle 
glaucoma. An average of 54.8% IOP reduction was observed within 2 h treatment; 
notably comparable to the 49.7% IOP reduction seen with intensive pilocarpine 
treatment (1-2 drops every minute for 5 min, every 5 min for 30 min)[75].  
More recently, the potential delivery of hyaluronic acid from CLs was assessed for 
the treatment of dry eye syndrome. The HG CLs loaded with HA exhibited release 
for up to 48 h; whilst maintaining the physical properties of the lens. In vivo release 
pharmacokinetics in rabbit tear fluid demonstrated effective increase in HA residence 
time in comparison to HA eye drops[81].  
In an attempt to retard the diffusion of hydrophilic drugs from CLs for sustained 
release, vitamin E (VE) has been incorporated into lens matrices to provide a 
hydrophobic barrier[66,77,82-85]. Soaking of lens in VE:ethanol solution prior to drug 
loading poses a barrier to the drug molecules when diffusing out of the matrix 
presenting the potential for sustained drug delivery; advantageous for conditions 
where frequent doses are essential.   
Cystinosis is a rare genetic condition which mostly affects children in which the 
amino acid ‘cysteine’ accumulates in vital organs (eye, kidney, pancreas and brain). 
Hsu et al developed lenses loaded with cysteamine with incorporation of VE to 
achieve sustained drug release[83]. Addition of VE increased drug duration from 10 
minutes to 3 h in solution. The lenses exhibited therapeutic concentration of the drug 
within 2 h of the lenses being worn; mimicking the action of hourly eye drops. Hsu et 
al also demonstrated that 20-30% of VE increased the release of moisturising agent 
dexpanthenol and osmoprotectant (compatible solutes that restore cell volume, 
stabilise proteins and protect cells from hyperosmolarity stress[86]) betaine from 
silicone lenses to 10 h; 60 times longer than unmodified lenses[84]. Topical 
anaesthetics such as lidocaine, bupivacaine and tetracaine (all hydrophilic at 
physiological pH) were loaded into VE soaked lenses[82]. These lenses continually 
released drug for 1-7 days, beneficial for post-operative pain of corneal surgery.  
Along with impeding drug diffusion, VE aggregates can provide UV protection to the 
cornea without altering lens transparency. Operating at a wave length smaller than 
that of visible light ensures there is no obstruction with respect to vision[87]. Although 
the method of soak and release has been met with various successes, the main 
challenge is to achieve and maintain the controlled release kinetic.    
 
Molecular Imprinting 
Molecular Imprinting (MI) is a novel technique which involves creating template 
nano-cavities within the lens matrix, which are subsequently used in molecular 
recognition. Incorporation of functional monomers (e.g. methacrylic Acid (MAA)) on 
polymer backbone advances drug affinity to the lens by providing sufficient binding 
sites for drugs[88]. Selection of functional monomer is crucial; they must be 
compatible with respect to lens material whilst having high affinity to the active. The 
process of MI is based on arranging the functional monomer around the drug 
molecules during polymerisation, creating a fixed, rigid structure due to the cross-
linking stage in polymerisation[88]. The drug and any unreacted monomers are 
extracted leaving behind nano-cavities that only have molecular recognition for that 
particular drug. The lens can then be loaded by soaking in drug solution. MI is also a 
sought out technique as it enhances the spatial arrangement of the lens matrices, 
ensuring maximum drug loading.  
Timolol has been used with MAA acting as the functional monomer and ethylene 
glycol dimethacrylate (EDGMA) as cross-linker due to its ionic interaction with 
timolol[6,72,89,90]. Hiratani et al were among the first to evaluate the in vivo potential of 
MI N-N-diethylacrylamide lenses[72,91]. Using different concentrations of the cross 
linker EGDMA, Hiratani et al utilised the MI method to increase timolol loading 
capacity. Imprinted contact lenses increased hydrogels affinity for timolol with 
prolonged drug release in the tear fluid of rabbits. Timolol from MI lenses was 
detected for 180 minutes; 2 fold longer than that found by non-imprinted lenses and 
3 times longer than the 60 minutes observed with 0.25% aqueous eye drops[72]. The 
same team also prepared imprinted HGs that increased the uptake of broad-
spectrum antibiotic norfloxacin (300 fold) using acrylic acid as the monomer[92].  
Other therapeutic agents have also benefitted from MI; including NSAIDs (where a 
10 fold increase ibuprofen and diclofenac loading capacity with sustained release for 
up to a week was observed[93]) and antibiotics (e.g. polymyxin B and vancomycin[94], 
ciprofloxacin[95,96]).  
Hui et al developed imprinted lenses with acetic and acrylic acid (the functional 
monomer( that extended the release duration of ciprofloxacin to 3-14 days[95]. Using 
various ratios of acetic acid to ciprofloxacin solution, Hui et al also developed MI 
silicone lenses[96]. Compared to non-imprinted lenses, the modified lens matrices 
released ciproflaxcin for a considerably longer time (P<0.05). The MI lenses were 
evaluated for the ability to inhibit gram negative bacterium Pseudomonas 
aeruginosa. Lenses loaded with 0.3% ciprofloxacin demonstrated complete bacteria 
inhibition for initial 2 days; showing inhibitory concentrations of drug were being 
reached/release from the lenses. However, after day 3, an increase in the bacterial 
concentration was observed; this was thought to be due to the reduction of 
ciprofloxacin concentration after being released from the lenses. Although 
differences in bacteria population was observed when comparing both non-imprinted 
lenses and MI lenses; they were not statistically significant (P>0.05)[96].    
 
Modifying Lens Matrix Composition/ionic interactions 
The permeability of ocular therapeutic agents can be affected by their charge under 
physiological conditions. Modifying the lens composition and exploiting the ionic 
interactions of functional monomers can potentially aid in achieving sustained or 
controlled drug release[97]. A common approach in this respect is to incorporate 
monomers based on hydrophilicity and ionic nature. Variations in these side groups 
ultimately affect the final properties of the HG lenses; subsequently the monomer 
used and its ratios can be altered to achieve specific criteria/use. Incorporating 
cationic or anionic functional monomers (also known as ligands), can increase the 
weak interactions (e.g. hydrogen bonding, electrostatic forces), allowing the HG 
matrices to store charged drugs on the basis of ion exchange reactions. Ergo, the 
percentage of HG matrix that is made up of ligands will be directly proportional to the 
drug loading efficiency[97].  
MAA is the most common ligand used to increase the ionic interactions in lenses; 
most prominent in pHEMA lenses. It is highly hydrophilic and anionic. Release 
kinetics of various ophthalmic drugs from MAA-loaded lenses has been studied 
numerous times; all yielding promising results[98-100]. Uchida et al have developed 
contact lenses using hydrogels with cationic functional group on the side chain 
(using methacrylamidopropyltrimethylammonium chloride (MAPTAC) and 2-
hydroxyethyl methacylate to obtain the cationic group)[98]. Hydrogels were capable of 
storing azulene (anionic drug), by the effect of ion exchange reaction, and releasing 
the drug under physiological conditions. There was a problem related to the size 
change of the hydrogel pre- and post- drug release; changes which were prevented 
by adding anionic monomers MAA and 2-methacryloyloxyethyl phosphate (MOEP) to 
the matrix[98]. MAA and MOEP were also added to pHEMA lenses resulted in 
extended release of naphazoline (a cationic vasoconstrictor). About 85% of the drug 
was released for 14 h, with the uptake of drug increasing by increasing the amount 
of anionic ligands within the matrix[99].  
Modifying pHEMA soft lenses with functional monomers (different concentrations of 
MAA or N-vinyl-2-pyrrolidone (NVP)) was used to assess the in vitro release kinetics 
of corticosteroid triamcinolone acetonide[100]. The modified lenses with MAA 
exhibited similar swelling behaviour in physiological conditions; however, MAA-
containing lenses demonstrated higher degree of swelling with the change in pH. 
This is a result of repulsive forces contained by the hydrogel generated by ionisation 
of carboxyl groups of MAA residues. Moreover, MAA lenses showed the best drug 
loading and the fastest drug release when compared with NVP hydrogels.  
On basis of the ion-ligand mechanism, the in vitro uptake of antibiotic agents’ 
gatifloxacin (GFL) and moxifloxacin (MFL) was assessed[101]. The drug uptake 
seemed to increase as percentage weight of anionic MAA increased. Initial burst 
release kinetics was observed from the modified lenses. In vivo studies exhibited 
greater drug concentration in cornea (GFL: 0.89µg/mL, MFL: 2.22µg/mL) and 
aqueous humour (GFL: 4.1µg/mL, MFL: 9.35µg/mL) after 24 hours when compared 
to antibacterial eye drops with the same antibacterial agents, which indicate an 
improvement in penetration into the eye.  
Whilst the previous studies focussed on incorporating the ligands via 
copolymerisation, another novel concept was proposed in order to improve the 
release of ionic drug for more than 2 hours by using surfactants.  Generally, this can 
be done by creating a high surface charged lens by adsorbing an ionic surfactant on 
the hydrogel matrix increasing the sustained release for an extended time. For 
instance, pHEMA CLs were developed for the controlled release of anionic drug 
dexamethasone 21-disodium phosphate using the cationic surfactant cetalkonium 
chloride. The drug release time was significantly improved from 2 h to 50 h[102].  
Altering the composition of the matrix can also solve the issue of low oxygen 
permeability. Ocular hypotensive (timolol) and steriod (dexamethasone) have been 
released at a sustained rate from lenses when silicone polymers have been used to 
replace conventional lens material (pHEMA)[76]. Silicone polymers are highly 
advantageous with regards to O2 permeability but can encounter problems with lack 
of patient compliance as a result of decreased water content leading to stiffness of 
the lens[103].  
Colloidal Carriers and Nanocarriers 
The arena of nanotechnology has already been successfully exploited in drug 
delivery for an array of therapeutic applications e.g. transdermal[104], nasal[105] and 
ocular[5]. The concept has extended to ocular drug delivery via contact lenses in the 
form of nanoparticles (NPs), surfactants, liposomes and cyclodextrins. The nature of 
these nano-carriers can protect sensitive materials from harsh external environments 
and can prevent drug degradation; the active can exist in an environment they would 
otherwise be unstable in. The sizes of these colloidal carriers also prove 
advantageous; patients’ vision is not compromised upon administration. The most 
common types of NPs are either lipid-based or polymeric-based.  
 
Liposomes: 
Liposomes are amphiphilic, closed bilayer phospholipid vesicles. They consist of a 
hydrophilic core and surface within internal hydrophobic ring. Their amphiphilic 
nature enables to encapsulate both hydrophilic and lipophilic drugs whilst their high 
thermodynamic stability can achieve high drug loading capacity with subsequent 
extended drug release[106]. Liposomes also have the ability to change their size 
(20nm to few µm), zeta potential as well as their surface charge; allowing these 
carriers to be customised for specific applications. They are usually incorporated into 
the pre lens or post lens region of the eye; retarding diffusion in both directions i.e. 
extended/sustained release[65]. The interaction between liposomes and cornea was 
first investigated by Schaeffer and Krohn in 1982[107]. They found that corneal 
liposome uptake was greatest with positively charged liposomes, suggesting 
preliminary interaction is electrostatic adsorption; the uptake of water soluble 
penicillin G was increased 4 fold using positively charged unilamellar liposomes[107].  
One of the first attempts to use liposomes for ocular topical drug delivery was for the 
treatment of acute and chronic herpetic keratitis; where Smolin et al found the 
delivery of idoxuridine was more effective with liposomes than without[108,109].  
Liposomes were first used in conjunction with soft CLs by Gulsen et al[73]. Lidocaine 
was entrapped in the lipid bilayer of dimyristoyl-phosphatidylcholine liposomes; 
subsequently loaded into pHEMA lenses. The lenses remained transparent and 
exhibited initial burst release (due to free drug) followed by sustained release from 
entrapped drug for up to 8 days[73].  
A group in Canada demonstrated sustained release of levofloxacin (6 days) by 
incorporating the drug into liposomes which were immobilized on to the surfaces of 
soft CLs[110]. The same research team immobilized intact liposomes onto multi-
layered CLs[111]. Polyethylenmine was first covalently bound to Hioxifilcon B lenses 
(via hydroxyl groups). NHS-PEG-biotin molecules were attached to the amide 
surface groups onto which protein Neutr-Avidin was bound. The intact liposomes 
(loaded with PEG-biothylated lipids were docked onto surface immobilized Neutr-
Avidin; further exposure to Neutr-Avidin and liposomes yielded multi-layered soft 
CLs[111].  
 
Niosomes 
Niosomes are highly stable, biodegradable, bi-layered vesicles. They possess a 
bilayer structure and assemble due to non-ionic surfactant and cholesterol 
interaction in the aqueous phase. In recent years, the use of niosomes as carriers to 
achieve sustained ocular drug release has increased. Li et al from China utilised 
niosomes for the delivery of Tacrolimus (FK506)[112]. Poloxamer 188 and lecithin 
were employed as surfactants and cholesterol as the stabiliser. The FK506 loaded 
niosomes showed no irritation and exhibited significantly increased drug retention 
time compared to 0.1% FK506 commercial ointment.  
Spherical cationic niosomes (200nm) loaded with PCMSEGFP plasmids successfully 
transfected HEK-293 and ARPE-19 cells without affecting the viability of said cells 
following intravitreal and subretinal injections[113]. This plasmid has also been 
incorporated into niosome/DNA vectors loaded with protamine[114]. These niosomes 
were 150nm (average) in size and spherical in shape. Upon administration in the 
eye, the EGFP expression was detected in different retinal cell layers with lack of 
toxicity. Intravitreal administration of niosomes demonstrated more uniform 
distribution of protein expression through inner retina which was exhibited for at least 
one month.  
 
More recently, cationic lipids were used to evaluate the use of niosomes on 
transfection efficiency in rat retina and brain[115]. Formulations containing lipids with a 
dimethylamine ethyl pendent showed greater transfection efficiency in ARPE-19 cells 
and PECC cells than lipids containing primary amine group or triglycine group. In 
vivo studies involving subretinal and intravitreal injection demonstrated promising 
transfection efficiencies.  
 
Polymeric Micelles 
Surfactants are amphiphilic entities which have the ability to solubilise aqueous and 
lipophilic drugs/material. During polymerisation of matrix for CLs, the incorporated 
surfactants come together forming spherical micelles with a hydrophobic core and a 
hydrophilic shell. Hydrophobic molecules occupy the space within these micelles 
during polymerisation, enabling the drug to remain in an environment in which it 
would otherwise be unstable. Entrapment of drug using this method retards drug 
diffusion; providing sustained release[116]. Surfactant molecules consist of a 
hydrophilic head connected to a hydrophobic tail; which interacts with the CL matrix, 
creating lenses with charged surfaces. This can help enhance drug loading; charged 
drugs can adsorb onto these charged surfaces hence extended drug release[117].  
A HG containing silica shell cross-linked methoxy micelles (SSCM) were developed 
in which polycaprolactone formed the core and silica constructed the shell of the 
micelles[118]. The SSCMs were loaded with dexamethasone acetate (hydrophobic 
nature) before they were incorporated into HGs. The release rate of the drug from 
the HGs was observed for up to 30 days. About 97% of the drug was released within 
10 hours with 60% being released within 8 hours via burst release. The same 
research group used Cyclosporine A to study the potential development of pHEMA 
lenses for the controlled release using various Brij surfactants[22,119]. Focussing on 
how chain length of surfactant affects the HG, Brig 78 exhibited the longest release 
rate (70% after 50 days) compared to pure pHEMA (90% in less than 10 days)[119]. 
Cyclosporine A was also used as a model ophthalmic drug to develop surfactant-
laden lenses where the effect of thickness of the lens on drug release was also 
assessed[22]. 100µm thick lenses indicated extended release of 7-8 days (2% Brij 78) 
and 16 days (8% Brij 78) whilst with 200µm thick lenses, the release rate was 
extended to 16-17 days and 40 days for 2% and 8% surfactant, respectively[22].  
 
Nanoparticles 
Nanoparticles are colloidal carriers on the nanoscale. Trapping API’s within NPs 
before dispersion through the hydrogel matrix provides a degree of protection to the 
drug from interaction with the hydrogel itself during                                                                          
polymerisation. Gulsen et al developed lidocaine-loaded NPs using hexadecane 
microemulsions (stabilised with silica shell). These NPs enabled the initial burst 
release of lidocaine where 50% of drug was released within the first few hours. This 
was followed by 80% of drug being released after 5 days [120].  
More recently, silicone hydrogels have been loaded with propoxylated glyceryl 
triacrylate (PGT) NPs containing timolol, a beta-blocker used in the treatment of 
glaucoma. It was observed that a HG with 5% drug loading was able to delivery 
timolol at the therapeutic concentration for 1 month at room temperature, 
preliminarily[121]. In vivo testing in glaucomatous beagle dogs demonstrate a 
reduction in IOP but release was much faster at higher temperatures (>40°C), 
releasing almost 100% within 3-4 days. This is thought to be due to the ester links 
between the timolol and PGT[121].   
Nanocrystals (100nm) of bovine serum albumin coated meloxicam (NSAID) were 
prepared and dispersed in pHEMA HG for the treatment of post cataract 
endophthalmitis. The gel released the meloxicam-nanoaggregates for approximately 
5 days in which the thickness of the lens and degree of cross-linking were the 
dependent variables of drug release and by altering these; the drug release rate 
could be optimised[122]. 
Silver NPs have also been embedded into lenses to enhance the antimicrobial 
properties of lenses. In vitro testing using Pseudomonas aeruginosa and 
Staphylococcus aureus demonstrated great antimicrobial effects against P. 
aeruginosa but only lenses with increased concentration of silver NPs were effective 
against S. aureus at 48 and 72 h[123].  
 
More recently, anti-fungal agent voriconazole was loaded into lipid-based NPs[124]. 
The resulting NPs were 182.0±4.1nm in size. The poorly water soluble active was 
readily released from the nanocarrier and inhibited the reproduction of fungus.  
Lipid NPs were also utilised to encapsulate indomethacin for delivery to anterior and 
posterior segment ocular tissues[125]. The resulting particles (266±5nm) achieved 
encapsulation efficiency of 81.0±0.9%. Modifying the lipid NPs with chitosan 
hydrochloride increased the ocular penetration of indomethacin; showing these 
nanocarriers as potential vehicles in ocular drug delivery.  
 
Cyclodextrins 
Cyclodextrins (CDs) are oligosaccharides made up of glucose units linked via α 1,4 –
glycosidic bonds. These cyclic structures are categorised based on the number of 
glucopyranose units they possess; α-CDs, β-CDs or γ-CDs. Their cyclic structure 
enables the entrapment of hydrophobic drugs (e.g. puerarin[126] and ethoxzolamide 
[127,128]) resulting in increased drug bioavailability, stability along with reducing 
potentials of undesirable side effects.  Ribeiro et al exploited the ability for natural β-
CDs and γ-CDs to form inclusion complexes with carbonic anhydrase inhibitors 
acetazolamide and ethoxzolamide in aqueous solution and developed N-N-
dimethylacrylate-co-N-vinylpyrrolidone lenses with these pendant CDs[128]. 
Incorporation of CDs had no lasting effect on optical transparency of the lenses or on 
the cytocompatiblity of the lenses. Acetazolamide-loaded HG sustained release for 
3-6 h whilst ethoxzolamide HGs sustained release for over a week[128]. 
Ethoxzolamide was also loaded into poly-CDs which notably enhanced drug 
solubility and provided much more delayed drug release rate compared to free 
CDs[127]. The poly-CDs also enhanced drug loading; resulting in sustained release 
for several weeks.  
Puerarin β-CD complexes were successfully loaded into pHEMA lenses where in 
vitro and in vivo studies showed drug- β-CD complexes were 7.2 times and 4 times 
as effective as eye drops and isolated lenses, respectively (concentration of drug in 
vitreous humour was around 46.55µg/mL)[126]. Drug loading was found to be 
depended on the β-CD content; as was the in vitro release of puerarin. In vivo 
analysis showed that drug retention in precorneal region was enhanced with greater 
bioavailability using β-CD loaded pHEMA lenses[126].  Puerarin was also used to 
synthesise cyclodextrin-containing hydrogels for ophthalmic drug delivery. The 
amount of puerarin loaded into HG matrix using a crosslinkable chitosan derivative 
containing β-CD was greatly increased and the release was much more controlled 
with the addition of the CD[129].  
More recently, conventional and silicone lenses (synthesized with methacrylated β-
CD and methacrylated 2-hydroxypropyl-β CD) were loaded with natamycin and its 
release was assessed. These lenses improved drug release up to a threshold 
despite not extending the drug release duration[130].  
 
Engineering Methods to Coat Lenses 
Rather than incorporation of drug into the lens matrix, there have been attempts to 
coat the surface of lenses in a bid to revolutionise ocular topical drug delivery. This 
approach has been met with promising results[5,131-134]. For instance, rapamycin is an 
immunosuppressant agent used for prevention of organs transplant rejection. It was 
incorporated into a poly (lactic-glycolic acid) (PLGA)-chloroform solution, which was 
subsequently sprayed on the edge of poly-(methyl methacrylate) (PMMA) lens in an 
attempt to prevent formation and development of posterior capsular opacification 
(PCO). Unmodified lenses (group A) and PLGA lenses (group B) served as controls 
and group C was the rapamycin-sprayed lenses.  After 7 days, the mean 
concentration of rapamycin in aqueous humour reached 1.10±0.30µ/mL after 
peaking to 14.57±0.99µg/mL after 24 h after administration to albino rabbits. In vivo 
analysis showed that the initial detection of PCO in rabbits in group C was much 
later than in groups A and demonstrating effective prevention of PCO formation and 
development[131].  
HEMA lenses have been exposed to octadecyl isocyanate (OI) solution where it was 
established that the polyurethane bonds between the hydroxyl groups on the HEMA 
lenses and the isocyanate groups retarded norfloxacin release. Immersion of lenses 
in OI solution for 60 minutes led to more than 90% of the drug being released within 
2 h; although this is rapid, it is slower than non-coated lenses[133]. Coating of PMMA 
lenses (with amino groups) with poly (sodium 4-styrene sulfonate) and ampicillin 
enhanced drug release with a 6-layer coating provided sustained release for 7 days 
(105µg of ampicillin)[134].  
Electrohydrodynamic atomisation (EHDA) is a novel technique was utilised to 
develop multi-functional ocular lenses. It employs electrical forces to atomise liquid 
to produce nano- and micro-metre structures. This is such a technique which the 
maturing area of nanotechnology has already exploited and benefitted from[135,136]. 
EHDA was used to produce poly-(vinyl pyrrolidone) (PVP) NPs (50-130nm) and PVP 
fibres (130-250nm) to coat both sides of the contact lens. As PVP is a rapidly 
dissolving polymer, the release was over 80% within 2 minutes with fibres 
demonstrating slightly longer sustained release due to lower surface area[5].  
 
Contact Lenses as theranostic devices 
The use of contact lenses has been exploited further than just vision correction and 
therapeutic applications. Recent research has extended to using contact lenses for 
the purpose of diagnostics and monitoring various chemical components present in 
the eye[7,137,138] (Table 3). In the early 21st century, Miller and Wilson developed a 
novel, non-invasive technique for intraocular drug detection[139]. Commercial lenses 
were optimised to direct light across the anterior chamber of the eye of rabbits. The 
eye effectively acted as a cuvette enabling optical absorbance to be measured, 
giving an indication to the drug concentration in the eye[139].  
Various attempts have been made to monitor glucose levels in situ using contact 
lenses. A team in USA designed contact lenses with integrated glucose sensor by 
creating cavities on the polymeric substrates which were then shaped into contact 
lenses. These devices exhibited quick responses, high sensitivity and good 
reproducibility[140]. Kudo et al reviewed the development of soft contact lens 
biosensor which consisted of film electrodes on the surface of poly dimethyl siloxane 
(PDMS) lens with glucose oxidase being immobilised around the electrodes, 
monitoring tear glucose when inserted in the eye[141]. Biocompatible lenses with 
PDMS as the glucose sensor have been fabricated and assessed on rabbits where a 
basal glucose level of 0.11mM was observed[142]. An oral glucose test was 
conducted to demonstrate the accuracy of the device which showed an elevation in 
glucose level with a delay of 10 mins.  
More recently, the arena of theranostics has exploited the nanotechnology platform. 
Gold nano-antennas were coated with boronic acid HG (which swells in the presence 
of glucose). The high sensitivity to low glucose of this formulation is highly 
advantageous; the functionalised HG was highly specific to glucose (due to the 
boronic acid) hence the presence of other molecules (e.g. protein, salts) was 
irrelevant in detection of glucose. This novel approach highlights the potential of 
plasmonic nano-structures as biosensors for glucose detection in tear fluid[137].  
A research team in Sweden developed dual-functional hybrid surface to modulate 
and detect a pathogenic attack. Mak et al employed a facile layer-by-layer surface 
engineering technique which enabled the device to capture inflammatory cytokines 
(e.g. interleukin 1-α) specifically for non-invasive diagnostics. The lenses showed 
effective anti-HSV-1 activity and good analytical performance for interleukin 1-α 
detection[138].  
 
Conclusion: 
This review has scrutinized the key systems and methods utilised for ocular drug 
delivery, with greater emphasis on drug delivery via contact lenses. The potential 
and drawbacks of more conventional methods (eye drops, emulsions, and gels) were 
also discussed. Constant evolution in material knowledge encourages the advancing 
therapeutic approaches in ocular drug delivery, forging novel pioneering ways to 
improve drug bioavailability and overcome the physiological and anatomical barriers 
of the eye. Current advancements in the ocular drug delivery remit show great 
potential and constant development of materials, equipment and processes in the 
pharmaceutical industry can aid the innovations in ocular drug delivery; resulting in 
promising potential products. 
 
 
Executive Summary: 
 Eye structure 
o This section is a brief explanation of the complexity of eye 
structure  
 Routes of Administration in Ocular Drug Delivery 
o The three main routes of for drug delivery are clarified and 
summarised; with advantages and disadvantages of each route.  
 Conventional Methods 
o This section has summarised existing methods currently used to 
topically treat ocular conditions with some examples currently 
being researched.  
 Eye Drops 
 Emulsions 
 Viscoelastic Gels 
 Innovative Systems 
 Implants  
 Iontophoresis 
 Microneedles 
 Contact lenses: 
o This section focuses is on contact lenses; composition, contact 
lenses as drug delivery systems, different drug loading 
mechanisms alongside utilising contact lenses in theranostics.  
 
Reference Annotations 
 
 Reference 5** Mehta P, Justo L, Walsh S, et al. New platforms for multi-functional 
ocular lenses: Engineering double-sided functionalized nano-coatings. J Drug 
Target. 23(4), 305-310 (2015). 
o Combining 2 processes and materials (EHDA, Contact Lenses) to develop a 
novel, innovative drug delivery device 
 Reference 34** Lallemand F, Daull P, Benita S, Buggage R, Garrigue J. Successfully 
improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug 
Deliv. 2012604204 (2012). 
o Commercial products show the potential of emulsions for improved drug 
delivery in practise.  
 Reference 60* Jiang J, Gill HS, Ghate D, et al. Coated microneedles for drug 
delivery to the eye. Invest.Ophthalmol.Vis.Sci. 48(9), 4038-4053 (2007). 
Reference 61* Kim YC, Grossniklaus HE, Edelhauser HF, Prausnitz MR. Intrastromal 
delivery of bevacizumab using microneedles to treat corneal neovascularization. 
Invest Ophthalmol Vis Sci. 55(11), 7376-7386 (2014). 
o These two papers combine 2 relatively novel methods to produce a whole 
new delivery system with promising results.  
 Reference 70** Wheeler J, Woods J, Cox M, Cantrell R, Watkins F, Edlich R. 
Evolution of hydrogel polymers as contact lenses, surface coatings, dressings, and 
drug delivery systems. 
Reference 71** Vanderlaan DG, Nunez IM, Hargiss M, Alton ML, Willams S, 
inventorsSoft Contact Lenses. patent US 5998498 A. 07/12/1999, 1999 
o These papers document the first look at the potential of hydrogels as 
contacts lenses and drug delivery systems  
 Reference 139* Miller J, Wilson CG, Uttamchandani D. Minimally invasive 
spectroscopic system for intraocular drug detection. J Biomed Opt. 7(1), 27-33 
(2002). 
Reference 142* Chu MX, Miyajima K, Takahashi D, et al. Soft contact lens 
biosensor for in situ monitoring of tear glucose as non-invasive blood sugar 
assessment. Talanta. 83(3), 960-965 (2011). 
 
o These papers show how research has now gone beyond just therapeutics; 
combining therapeutics and diagnostics in the pharmaceutical remit; 
yielding a whole new application of contact lenses 
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Figure 1: Systematic diagram depicting drug delivery approaches in topical ocular drug delivery. 
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Table 1: different loading mechanisms of different drugs. 
Mechanism of 
Drug loading  
  
Lens 
Material 
Active Reference 
Number 
  
Name Function 
soak and release "Sauflon" Hydrophilic lenses (vinyl pyrollidone/acrylic copolymer) Pilocarpine Anti-glaucoma 74 
Silicone: N,N-dimethylacrylamide, 3-
methacryloxypropyltris(trimethylsiloxy)silane, bis-alpha,omega-
(methacryloxypropyl) polydimethylsiloxane, 1-vinyl-2-pyrrolidone, ethylene 
glycol dimethacrylate  
Timolol, 
Dexamethasone, 
Dexamethasone 
21-acetate 
Anti-glaucoma 75 
ACUVUE® TruEye™ Timolol Anti-glaucoma 76 
NIGHT AND DAY™ Silicone Hydrogel lenses Timolol  Anti-glaucoma 77 
Balafilcon A, Etafilcon A, Etafilcon A Daily Disposable,  
Nelfilcon A, comfilcon A 
Ketotifen 
Fumarate 
anti-allergy 78 
silicon lenses containing (Lotrafilcon and balafilcon) and p-HEMA-containing 
(etafilcon, alphafilcon, polymacon, vifilcon and omafilcon) 
Cromolyn 
sodium, ketotifen 
fumarate, 
ketorolac 
tromethamine, 
dexamethasone 
sodium 
phosphate 
NSAID, Anti-
histamine, 
corticosteroid 
79 
Lotrafilcon A, Galyfilcon A, Senofilcon A, Lotrafilcon B, Balafilcon A  Dexamethasone 
21-disodium 
phosphate, 
timolol maleate, 
flucnazole 
Corticosteroid, 
Anti-glaucoma, 
anti-fungal agent 
65 
HEMA, EGDMA, MAA Hyaluronic Acid Dry Eye 92 
Lotrafilcon B Lidocaine, 
bupivacaine, 
tretracaine 
Anesthetic 93 
Narafilcon B (silicone), Senofilcon A (silicone), Lotrafilcon B (silicone), 
Balafilcon A (silicone),Etafilcon A (p-HEMA )  
cysteamine 
hydrochloride 
Cytinosis 94 
Senofilcon A (silicone), Narafilcon B Betaine, 
Dexpanthenol 
Ocular Dryness 83 
Senofilcon A (silicone), Lotrafilcon A (silicone), Lotrafilcon B (silicone) Dexamethasone  NSAID 84 
Molecular 
Imprinting 
HEMA Timolol maleate Anti-glaucoma 71,89 
HEMA Timolol Anti-glaucoma 103 
poly (hydroxyethyl methacrylate) norfloxacin Antibiotic 90 
HEMA polymyxin B, 
vancomycin 
Antibiotic 92 
SCL  ciprofloxacin Antibiotic 93 
HEMA ciprofloxacin Antibiotic 94 
Modifying Matrix 
Composition 
HEMA Azulene   95 
HEMA Naphazoline Sedative 97 
pHEMA Triamcinolone 
acetonide 
corticosteroid 98 
SCL Gatifloxacin, 
Moxifloxacin 
Antibiotic 99 
pHEMA Dexamethasone 
21-disodium 
phosphate 
corticosteroid 100 
Liposomes pHEMA lidocaine Anaesthetic 83 
Hioxifilcon B levofloxacin Antibiotic 108,109 
Surfactants pHEMA Dexamethasone 
acetate 
corticosteroid 112 
pHEMA Cyclosporin A immunosuppress
ant  
113 
pHEMA Cyclosporin A immunosuppress
ant  
22 
Nanoparticles pHEMA lidocaine Anaesthetic 114 
pHEMA lidocaine Anaesthetic 115 
Silicone: N, N-Dimethylacrylamide, 1-vinyl-2-pyrrolidone, 3-Methacyloxypropyl-
tris (trimethylsiloxy)silane, MAA 
timolol maleate Anti-glaucoma 116 
pHEMA Meloxicam NSAID 114 
HEMA Silver Antimicrobial 
Agent 
118 
Cyclodextrins pHEMA Puerarin Anti-glaucoma 119 
HEMA ethoxzolamide Carbonic 
Anhydrase 
Inhibitor 
120 
N,N-dimethylacrylamide-co-N-vinylpyrrolidone  ethoxzolamide, 
acetazolamide 
Carbonic 
Anhydrase 
Inhibitor 
121 
HEMA natamycin Anti-fungal Agent 123 
Engineering 
methods of 
coating lenses 
  
PMMA Rapamycin immunosuppress
ant  
124 
HEMA norfloxacin antibiotic 126 
PMMA ampicillin Antibiotic 127 
Balafilcon A Dye Probe 5 
 
SCL: silicon contact lenses, NPs: nanoparticles, IOP: intraocular pressure, HEMA: 2-hydroxyethyl methacrylate, pHEMA: poly 
(hydroxyethyl methacrylate), NVP: N-vinyl-2-pyrrolidone, MAA: Methacrylic acid, MOEP: 2-methacryloxyethyl acid phosphate,  
MAPTAC: methacrylamido-propyltrimethylammonium chloride, MPTS: 3-Methacryloxypropyltris(trimethylsiloxy) silane,  EGDMA: 
ethyleneglycole dimethacrylate, TRIS: 3-methacryloxypropyltris (trimethylsiloxy) silane, DMA: N,N-dimethylacrylamide, HA: 
hyaluronic acid, HG: hydrogel, DMPC: dimyristol-phosphatidylcholine, CAC: benzyldimenthylhexadecyl-ammonium chloride, 
MePEG-b-PCL: methoxy(polyethylene glycol)-block-polycaprolactone, CD: cyclodextrin, β-CD: β-cyclodextrin, PMMA: poly-(methyl 
methacrylate), PCO: posterior capsular opacification, PVP: poly-(vinyl pyrrolidone). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. ocular drug delivery using conventional methods 
 
Method Active Excipient Target Condition Reference 
Number 
Eye Drop Aceclofenac MP, PP, HPMC, PVA, 
BAC, PMN, PMA, BA, 
chitosan 
cornea, 
anterior 
chamber 
Anterior Chamber inflammation, 
post-surgery pain and inflammation 
16 
Dexamethasone  -- Intermediate 
and 
Posterior 
Uveitis  
Non-Infectious Uveitic macular 
oedema and vitritis 
17 
Prednisolone HPMC, Dimethyl-β-
cyclodextrin 
Cornea, 
posterior 
segment 
ocular infections, post cataract 
surgery antibiotic 
18 
Dorzolamide Disodium edetate 
dehydrate, monosodium 
phosphate dihydrate, 
benzalkonium chloride, 
HPMC 4000, Tyloxapol 
Cornea, 
aqueous 
humour 
glaucoma 19 
Ciprofloxacin  -- Primarily 
cornea 
Antibiotic 21 
Emulsions Timolol Maleate Octanoic acid, 1-butanol, 
isopropyl myristate, 1-4 
dioxane, egg lecithin 
aqueous 
humour 
glaucoma 24 
delta-8-
Tetrahydrocann
abinol 
Purified soy-bean oil, 
crude egg yolk 
phospholipids, Pluronic 
F-68, glycerin, α-
tocopherol 
aqueous 
humour 
glaucoma 30 
Cyclosporin A, 
latanoprost 
Cationic emulsion Primarily 
cornea 
Dry Eye 33,34 
Doxycycline 
hydrochloride 
Gellan Gum, Polyvinyl 
alcohol, 
dichloromethane, calcium 
chloride 
Corn Bacterial Infection 3 
Hydrogel gentamycin 
sulphate, 
dexamethasone 
Chitosan, Gelatin, BAC, 
Propylene glycol, 
Thioglycolate medium, 
Soybean casein digest 
Cornea, 
conjunctiva  
Conjunctivitis 37 
Bovine Serum 
Albumin 
Porcine type I 
atelocollagen, 
morpholinoethansulfonic 
acid, sodium alginate 
Cornea protein delivery 39 
latanoprost chitosan, gelatin, glycerol 
phosphate 
Cornea glaucoma 40 
Avastin Glycol Chitosan, Oxidise 
alginate,  
cornea, 
posterior 
chamber  
Age-related macular degeneration, 
proliferative diabetic retinopathy 
41 
timolol maleate chitosan, poly (n-
isopropylacrylamide),  
Cornea Glaucoma 46 
timolol maleate, 
brimonidine 
tartrate 
Poly acrylic acid, HPMC, 
sodium chloride, BAC  
Cornea glaucoma 47 
Ofloxacin PAA, Noveon AA-1 USP 
Polycarbophil 
Cornea acute conjunctivitis, bacterial 
keratitis, keratoconjunctivitis 
48 
sparfloxacin sodium alginate, 
methylcellulose,  
multiple eye 
tissue 
bacterial infection 4 
Moxifloxacin 
Hydrochloride 
Polyox, HPMC, 
Poloxamer, sodium 
alginate 
Primarily 
cornea 
bacterial infection 49 
Cromolyn 
Sodium  
Pluronic F 127, HPMC, 
carbopol 940, xanthan 
gum, sodium alginate 
Primarily 
cornea 
Inflammation 50 
MP: Methyl paraben, PP: Propyl Paraben, HPMC: Hydroxypropyl Methylcellulose, BAC: Benzalkonium Chloride, PMN: Phenyl 
mercuric nitrate, PMA: Phenyl mercuric acetate, BA: Benzyl Alcohol, γ-CD: gamma cyclodextrin, β-CD: beta cyclodextrin, PAA: 
Poly acrylic acid, HG: hydrogel, NSAIDs: non-steroidal anti-inflammatory drug, NPs: nanoparticles. 
 
 
 
 
 
  
 
Table 3: Theranostics Using Contact Lenses 
Method Probe/Detection Comments 
Reference 
number  
 -- Drug 
Commercial lenses were optimised to 
direct light to the anterior chamber of 
rabbit eyes; the eye acted to focus the 
light, allowing optical absorbance to be 
measured; hence obtaining drug 
concentration data.  
132 
Chip Glucose 
An electrochemical sensor was integrated 
into a functional contact lens which was 
based on the activation and deactivation 
of glucose oxidase. This chip was 
integrated into cavities in polymeric 
matrix; subsequently shaped into contact 
lenses. They exhibited quick responses 
and high sensitivity to tear glucose levels.  
133 
film  -- 
Film electrodes were attached to the 
surface of PDMS lenses. Glucose oxidase 
were immobilised on around the 
electrodes; monitoring tear glucose levels.  
134 
   -- 
Oral glucose test reiterated and confirmed 
the accuracy of PDMS as the glucose 
sensor incorporated into biocompatible 
lenses. 
135 
Antenna  -- 
The swelling of boronic acid hydrogels in 
the presence of glucose is highly 
advantageous due to high specificity to 
glucose; other materials in tear 
composition is irrelevant/would not 
compromise the data.   
130 
--  
inflammatory 
cytokines 
these lenses were developed specifically 
for non-invasive diagnostics for detection 
of pathogenic attack. The lenses also 
contained an antiviral coating to protect 
against disease as a first line of defence.  
131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Systematic diagram depicting drug delivery approaches in topical ocular 
drug delivery. 
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